Video
6 Jul 2022

Supporting the World's Biggest Challenges

Smart Science to Improve Lives. For more than 75 years Croda Denmark has been dedicated to safe and effective adjuvants for use in both human and veterinary vaccines, as well as blood fractioning processes. We offer an experienced passionate team and personal interaction with comprehensive on-site advice and support anywhere in the world.

Content provided by our supplier

Croda Europe Limited

  • GB
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Animal Health
Custom Manufacturing/Custom Synthesis
Excipients Manufacturer
Fine Chemicals Company

Other Content from Croda Europe Limited (3)

  • News Two new partnerships to drive sustainable delivery systems for the pharmaceutical industry

    Croda International Plc (Croda) today announced that it has signed two new partnership agreements that will help the pharmaceutical industry move towards a more sustainable supply chain for vaccine adjuvants. 
  • Brochure Addressing the challenges of vaccine formulation

    To this day, our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. This heritage makes our vaccine adjuvants unique in the industry. A heritage we are proud of. 

    Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.
  • Sponsored Content Croda: Solutions for Your High Value Drug Products

    Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.